Full text is available at the source.
Abstract
Semaglutide injections for weight management were marketed in Denmark in December 2022.
- Pre-marketing trials showed high efficacy of semaglutide when the treatment and dose adjustment guidelines were followed.
- The study examines the real-world application of semaglutide in primary care for adults with overweight or obesity.
- It focuses on dose titration, patterns of discontinuation, and the impact on body weight.
Simplified